- $9.6 BnWorld market, 2023
- $13.5 BnProjected, 2033
- 3.5%Growth a year (CAGR)
- 544Active clinical trials worldwide
Largest countries
Market size in 2023 · growth a year to 2033
-
1
US
$4 Bn
1.5% a year · 42% of the world -
2
China
$772 Mn
5% a year · 8% of the world -
3
Canada
$768 Mn
3.5% a year · 8% of the world -
4
Japan
$597 Mn
4% a year · 6.2% of the world -
5
Germany
$351 Mn
1.7% a year · 3.7% of the world -
6
France
$264 Mn
2.5% a year · 2.8% of the world -
7
UK
$250 Mn
1.5% a year · 2.6% of the world -
8
Brazil
$240 Mn
4.5% a year · 2.5% of the world -
9
Italy
$230 Mn
3% a year · 2.4% of the world -
10
Ecuador
$192 Mn
4.1% a year · 2% of the world
Most clinical trials
Active trials by country (ClinicalTrials.gov)
See every trial on ClinicalTrials.gov (opens in a new tab)Epilepsy Drugs by country and region
| Place | 2023 | 2033 (projected) | CAGR | World share | Active trials | Report |
|---|---|---|---|---|---|---|
| World | $9.6 Bn | $13.5 Bn | 3.5% | – | 544 | Report on Epilepsy Drugs in Global |
| North America | $4.8 Bn | $6.1 Bn | 2.5% | 50% | 235 | Report on Epilepsy Drugs in North America |
| APAC | $2 Bn | $3.2 Bn | 4.8% | 21% | 88 | Report on Epilepsy Drugs in APAC |
| Europe | $1.8 Bn | $2.3 Bn | 2.2% | 19% | 152 | Report on Epilepsy Drugs in Europe |
| Latin America | $432 Mn | $671 Mn | 4.5% | 4.5% | 16 | Report on Epilepsy Drugs in Latin America |
| Middle East | $384 Mn | $596 Mn | 4.5% | 4% | 3 | Report on Epilepsy Drugs in Middle East |
| Africa | $144 Mn | $235 Mn | 5% | 1.5% | 12 | Report on Epilepsy Drugs in Africa |
| US |
$4 Bn | $4.7 Bn | 1.5% | 42% | 224 | Report on Epilepsy Drugs in US |
| China |
$772 Mn | $1.3 Bn | 5% | 8% | 52 | Report on Epilepsy Drugs in China |
| Canada |
$768 Mn | $1.1 Bn | 3.5% | 8% | 23 | Report on Epilepsy Drugs in Canada |
| Japan |
$597 Mn | $883 Mn | 4% | 6.2% | 12 | Report on Epilepsy Drugs in Japan |
| Germany |
$351 Mn | $416 Mn | 1.7% | 3.7% | 23 | Report on Epilepsy Drugs in Germany |
| France |
$264 Mn | $338 Mn | 2.5% | 2.8% | 83 | Report on Epilepsy Drugs in France |
| UK |
$250 Mn | $290 Mn | 1.5% | 2.6% | 35 | Report on Epilepsy Drugs in UK |
| Brazil |
$240 Mn | $373 Mn | 4.5% | 2.5% | 10 | Report on Epilepsy Drugs in Brazil |
| Italy |
$230 Mn | $310 Mn | 3% | 2.4% | 47 | Report on Epilepsy Drugs in Italy |
| Ecuador |
$192 Mn | $288 Mn | 4.1% | 2% | 0 | Report on Epilepsy Drugs in Ecuador |
 Spain |
$185 Mn | $237 Mn | 2.5% | 1.9% | 26 | Report on Epilepsy Drugs in Spain |
 India |
$175 Mn | $328 Mn | 6.5% | 1.8% | 4 | Report on Epilepsy Drugs in India |
 Saudi Arabia |
$163 Mn | $266 Mn | 5% | 1.7% | 1 | Report on Epilepsy Drugs in Saudi Arabia |
 Mexico |
$144 Mn | $208 Mn | 3.8% | 1.5% | 9 | Report on Epilepsy Drugs in Mexico |
 Australia |
$115 Mn | $188 Mn | 5% | 1.2% | 27 | Report on Epilepsy Drugs in Australia |
 South Africa |
$62 Mn | $99 Mn | 4.7% | 0.7% | 1 | Report on Epilepsy Drugs in South Africa |
 UAE |
$48 Mn | $75 Mn | 4.5% | 0.5% | 2 | Report on Epilepsy Drugs in UAE |
 Egypt |
$27 Mn | $44 Mn | 5% | 0.3% | 10 | Report on Epilepsy Drugs in Egypt |
 Philippines |
$21 Mn | $31 Mn | 4% | 0.2% | 0 | Report on Epilepsy Drugs in Philippines |
 Hong Kong |
$15 Mn | $24 Mn | 4.5% | 0.2% | 1 | Report on Epilepsy Drugs in Hong Kong |
 Malaysia |
$15 Mn | $22 Mn | 3.7% | 0.2% | 1 | Report on Epilepsy Drugs in Malaysia |
 Singapore |
$12 Mn | $17 Mn | 4.1% | 0.1% | 1 | Report on Epilepsy Drugs in Singapore |
 Thailand |
$12 Mn | $17 Mn | 3.8% | 0.1% | 1 | Report on Epilepsy Drugs in Thailand |
 Kenya |
$7 Mn | $11 Mn | 4.6% | 0.1% | 1 | Report on Epilepsy Drugs in Kenya |
 New Zealand |
– | – | – | – | 0 | Report on Epilepsy Drugs in New Zealand |
 Russia |
– | – | – | – | 3 | Report on Epilepsy Drugs in Russia |
"–" means we have no size for that place yet. 2033 values are projected from the 2023 size and the CAGR. Regions count only the countries we report on for trials.
Latest research 19,729 papers since 2021
- Efficacy and tolerability of brivaracetam as adjunctive therapy in children with drug-resistant epilepsy: a single-center prospective cohort study. Journal of the Formosan Medical Association = Taiwan yi zhi, 2026
- Clinical features and outcomes in children with late-onset febrile seizures. Brain & development, 2026
- Automated intracranial spike analysis across sleep-wake states localizes the seizure onset zone in drug-resistant epilepsy. Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology, 2026
- Epigenetic age acceleration in the brain and blood of people with epilepsy and in a mouse model of focal cortical dysplasia: a retrospective cross-sectional study. EBioMedicine, 2026
- Azetukalner in Adults With Focal Seizures: The X-TOLE2 Phase 3 Randomized Clinical Trial. JAMA neurology, 2026
Compare Epilepsy Drugs side by side
Key companies in Epilepsy Drugs
Abbott Laboratories
GlaxoSmithKline PLC
Johnson & Johnson Health Care Systems Inc.
Novartis AG
UCB S.A.
Pfizer, Inc.
Bausch Health Companies Inc.
Teva Pharmaceutical Industries Ltd.
Sunovion Pharmaceuticals Inc.
Eisai Co.
Johnson & Johnson Health Care Systems Inc.
Novartis AG
UCB S.A.
Pfizer, Inc.
Bausch Health Companies Inc.
Teva Pharmaceutical Industries Ltd.
Sunovion Pharmaceuticals Inc.
Eisai Co.
Quick answers
How big is the Epilepsy Drugs market?
The world Epilepsy Drugs market was worth about $9.6 Bn in 2023 and is projected to reach $13.5 Bn by 2033, growing 3.5% a year (CAGR).
Which country has the largest Epilepsy Drugs market?
The US is the largest of the 24 countries we cover, at $4 Bn in 2023. India grows fastest, at 6.5% a year.
How many clinical trials are running in Epilepsy Drugs?
ClinicalTrials.gov lists 544 active trials worldwide (recruiting, about to start or running), most of them in the US, as of 10 Nov 2026.
How much research is published on Epilepsy Drugs?
PubMed lists about 19,729 papers on the topic since 2021.
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov. Research: PubMed (US National Library of Medicine). Fetched 10 Nov 2026. Trials and papers are found by search words, so counts are a guide.